# US 8,278,358 B2 · Lipoic acid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,358 B2
- Document ID: US8278358B2
- Status: Granted
- Kind: B2
- Application number: 11/772,278
- Filed: 2007-07-02
- Published: 2008-03-06
- Granted: 2012-10-02
- Earliest claimed: 2006-07-07
- Assignees: Omnica GmbH
- Inventors: Thomas Eidenberger
- Web page: https://patentgrep.com/patent/US8278358B2

## CPC

- C07C 323/52: the carbon skeleton being acyclic and saturated
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention describes alpha lipoic acid complexes, that can be oligomeric, polymeric, monomeric and mixtures thereof. The complexes can be salts, chelates, etc. of the oligomers, polymers, or monomeric alpha lipoic acid.

## Claims

### Claim 1

A composition comprising:
a stable complex of oligomeric lipoic acid and a counterion, wherein the average degree of oligomerization is between 2 and about 7 and has a melting point above that of monomeric lipoic acid and the counterion is a basic amino acid.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the basic amino acid is ornithine, arginine, lysine or mixtures thereof.

### Claim 3

A composition comprising:
a stable oligomeric lipoic acid complex and a counterion comprising formula (I):
wherein each R+ independently denote a counterion, and
n is a value between about 2 and about 50 and has a melting point above that of monomeric lipoic acid and the counterion is a basic amino acid.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the basic amino acid is ornithine, arginine, lysine or mixtures thereof.

### Claim 5

A stable oligomeric lipoic acid complex and a basic amino acid counterion prepared by the process of:
a) reacting a basic amino acid with lipoic acid in an aqueous solution;
b) maintaining the solution at an elevated temperature for a period of between about 1 to about 5 hours; and
c) precipitating a complex of the oligomeric lipoic acid and basic amino acid counterion from the aqueous solution by addition of a non-solvent wherein the degree of oligomerization is between 2 and about 50 and has a melting point above that of monomeric lipoic acid.

### Claim 6 (depends on 5)

The oligomeric lipoic acid complex of the process of claim 5, further comprising the step of:
d) collecting the precipitated complex.

### Claim 7 (depends on 5)

The oligomeric lipoic acid complex of claim 5, wherein the temperature of the reaction is between about 30° C. and about 50° C.

### Claim 8 (depends on 5)

The oligomeric lipoic acid complex of claim 5, wherein the solution was maintained at the elevated temperature for about 3 hours.

### Claim 9 (depends on 5)

The oligomeric lipoic acid complex of claim 5, wherein the non-solvent is an alcohol, a chlorinated hydrocarbon, an aliphatic ketone, an aliphatic ether, an alkyl hydrocarbon, an aromatic hydrocarbon or mixtures thereof.

### Claim 10 (depends on 9)

The oligomeric lipoic acid complex of claim 9, wherein the non-solvent is one of acetonitrile, dichloromethane, acetone, 2-propanol, diethyl ether, hexane, octane, toluene, petroleum ether, tetrahydrofuran, octanol, benzene, dioxane or mixtures thereof.

### Claim 11 (depends on 5)

The oligomeric lipoic acid complex of claim 5, wherein the amino acid is ornithine, arginine, lysine or mixtures thereof.

### Claim 12

A composition comprising:
a stable mixed oligomeric alpha lipoic acid complex and a counterion comprising formula (II):
wherein n is a value between about 2 and about 7 and has a melting point above that of monomeric lipoic acid; and
each R1 independently is a hydrogen atom or counterion provided at least one R1 is a counterion and the counterion is a basic amino acid.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 3)

A pharmaceutical composition comprising the composition of claim 3 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 5)

A pharmaceutical composition comprising the composition of claim 5 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 12)

A pharmaceutical composition comprising the composition of claim 12 and a pharmaceutically acceptable carrier.

### Claim 17

A composition comprising:
an isolated complex of oligomeric lipoic acid and a counterion, wherein the degree of oligomerization is between 2 and about 7 and has a melting point above that of monomeric lipoic acid and the counterion is a basic amino acid.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the basic amino acid is ornithine, arginine, lysine or mixtures thereof.

### Claim 19

A composition comprising:
an isolated oligomeric lipoic acid complex and a counterion comprising formula (I):
wherein each R+ independently denote a counterion, and
n is a value between about 2 and about 7 and has a melting point above that of monomeric lipoic acid and the counterion is a basic amino acid.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the basic amino acid is ornithine, arginine, lysine or mixtures thereof.

### Claim 21

A composition comprising:
an isolated mixed oligomeric alpha lipoic acid complex and a counterion comprising formula (II):
wherein n is a value between about 2 and about 7 and has a melting point above that of monomeric lipoic acid; and
each R1 independently is a hydrogen atom or counterion provided at least one R1 is a counterion and the counterion is a basic amino acid.

### Claim 22 (depends on 17)

A pharmaceutical composition comprising the composition of claim 17 and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 19)

A pharmaceutical composition comprising the composition of claim 19 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 21)

A pharmaceutical composition comprising the composition of claim 21 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the complex has a melting point up to between about 165° C. and 170° C.

### Claim 26 (depends on 3)

The composition of claim 3, wherein the complex has a melting point between about 165° C. and 170° C.

### Claim 27 (depends on 5)

The composition of claim 5, wherein the complex has a melting point between about 165° C. and 170° C.

### Claim 28 (depends on 12)

The composition of claim 12, wherein the complex has a melting point between about 165° C. and 170° C.

### Claim 29 (depends on 17)

The composition of claim 17, wherein the complex has a melting point between about 165° C. and 170° C.

### Claim 30 (depends on 19)

The composition of claim 19, wherein the complex has a melting point between about 165° C. and 170° C.

### Claim 31 (depends on 21)

The composition of claim 21, wherein the complex has a melting point between about 165° C. and 170° C.
